Forest Labs and Watson Pharma to Open Near 52-Week Highs

Forest Laboratories FRX and Watson Pharmaceuticals WPI reached new 52-week highs of $40.52 and $66.00 per share, respectively, in Wednesday's trading session. Forest Labs saw an upgrade from Argus and Duncan-Williams upgraded its price target on the stock to $45 in the wake of activist investor Carl Icahn's recent interest in the company. Forest Labs develops and manufactures name-brand as well as generic prescription and over-the-counter pharmaceutical products. It has a market cap of $11.4 billion. Its return on equity is 15.5% and the price-to-earnings ratio is 9.0. Short interest tumbled in March and is now about 4% of the float. The stock is about 25% higher year to date, outperforming competitors Eli Lilly LLY and GlaxoSmithKline GSK, as well as the broader markets. Watson saw a favorable ruling from a U.S. District Court in a patent infringement suit, and the company also just announced expansion plans for its R&D facility in Salt Lake City. The company has a market cap of $8.3 billion, and it develops, manufactures and markets globally generic and brand-name drugs focused on urology and women's health. The company has a P/E ratio that is much lower than the industry average, a PEG ratio of 1.1, and its long-term EPS growth forecast is 12.4%. The share price is up more than 26% since the beginning of the year, outperforming competitors Novartis NVS and Teva Pharmaceutical TEVA, as well as the broader markets, in that time.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Long IdeasShort IdeasPre-Market OutlookTrading Ideas52-Week Highsand Teva PharmaceuticalArgusCarl IcahnDuncan-Williamseli lillyforest laboratoriesForest LabsglaxosmithklineHealth CareNovartisPharmaceuticalsWatson Pharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!